Sysmex America Exhibits New Products, Automation and Quality Solutions
|
By LabMedica International staff writers Posted on 06 Aug 2019 |

Image: The PS-10, designed for complex laboratory-developed tests and routine flow cytometry applications (Photo courtesy of Sysmex America).
Sysmex America, Inc. (Lincolnshire, IL, USA), a diagnostic solutions company offering hematology, urinalysis and flow cytometry testing technology, exhibited its expanded line of products and services at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo.
At AACC 2019, Sysmex demonstrated its products, processes, automation, quality, and best practices in clinical laboratory management. Sysmex showcased its highly automated and flexible PS-10, which is designed for complex laboratory-developed tests and routine flow cytometry applications, providing clinical laboratories with a new level of workflow efficiency and confidence in accurate results. The PS-10 automates sample preparation, alleviating primary operational bottlenecks in busy clinical flow laboratories, as well as eliminating variability between operators. The PS-10 also offers standardization for antibody cocktailing and reduces the amount of manual transferring of samples performed by laboratory staff.
The company also demonstrated its complete blood count (CBC) analyzer, the XN-20, a complementary system to the XN-10, but with an additional analysis channel. The White Precursor Cell (WPC) channel, which provides improved differentiation of abnormal WBC populations, adds further efficiency for laboratories. Also on display at the tradeshow was the UN-2000, Sysmex’s first fully automated urine particle counter and digital imaging system that provides laboratories with a highly standardized and efficient process for urine sediment analysis, one with less manual intervention and greater accuracy. Using fluorescence flow cytometry, the UN-2000 reduces time consuming hands-on review, delivering highly accurate particle quantitation and differentiation through walk-away loading, standardized criteria with high reproducibility, quantitative measurement and automated validation helping the review of the technologist.
In software solutions, Sysmex demonstrated its quality management system BeyondCare Quality Monitor for Hematology (BCQMh), which streamlines the end-to-end process of running controls and reviewing results, leading to improved analyzer productivity. The web-based quality control and calibration verification management program uses evidence-based quality control. Sysmex also highlighted it powerful software solution Caresphere Laboratory Management (LM) for monitoring quality, productivity and efficiency data, enabling labs to optimize their performance. Bringing together crucial elements such as turnaround times, rerun ratios, analyzer conditions and performance metrics, Caresphere LM provides at-a-glance metrics and status updates designed to give labs the information they need without having to search through multiple software systems. Whether managing one site or many, accessing statistics and calibration data is made simple with Caresphere LM.
At AACC 2019, Sysmex demonstrated its products, processes, automation, quality, and best practices in clinical laboratory management. Sysmex showcased its highly automated and flexible PS-10, which is designed for complex laboratory-developed tests and routine flow cytometry applications, providing clinical laboratories with a new level of workflow efficiency and confidence in accurate results. The PS-10 automates sample preparation, alleviating primary operational bottlenecks in busy clinical flow laboratories, as well as eliminating variability between operators. The PS-10 also offers standardization for antibody cocktailing and reduces the amount of manual transferring of samples performed by laboratory staff.
The company also demonstrated its complete blood count (CBC) analyzer, the XN-20, a complementary system to the XN-10, but with an additional analysis channel. The White Precursor Cell (WPC) channel, which provides improved differentiation of abnormal WBC populations, adds further efficiency for laboratories. Also on display at the tradeshow was the UN-2000, Sysmex’s first fully automated urine particle counter and digital imaging system that provides laboratories with a highly standardized and efficient process for urine sediment analysis, one with less manual intervention and greater accuracy. Using fluorescence flow cytometry, the UN-2000 reduces time consuming hands-on review, delivering highly accurate particle quantitation and differentiation through walk-away loading, standardized criteria with high reproducibility, quantitative measurement and automated validation helping the review of the technologist.
In software solutions, Sysmex demonstrated its quality management system BeyondCare Quality Monitor for Hematology (BCQMh), which streamlines the end-to-end process of running controls and reviewing results, leading to improved analyzer productivity. The web-based quality control and calibration verification management program uses evidence-based quality control. Sysmex also highlighted it powerful software solution Caresphere Laboratory Management (LM) for monitoring quality, productivity and efficiency data, enabling labs to optimize their performance. Bringing together crucial elements such as turnaround times, rerun ratios, analyzer conditions and performance metrics, Caresphere LM provides at-a-glance metrics and status updates designed to give labs the information they need without having to search through multiple software systems. Whether managing one site or many, accessing statistics and calibration data is made simple with Caresphere LM.
Latest AACC 2019 News
- Instrumentation Laboratory Presents New IVD Testing System
- Quidel Welcomes Newest Member of Triage Family
- ERBA Mannheim Unveils Next-Generation Automation
- Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond
- BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics
- Thermo Shows New Clinical Innovations
- Randox Launches New Innovations
- Streck Introduces Three New Antibiotic Resistance Detection Kits
- EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring
- BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019
- MedTest Dx Releases New Product Line for Drugs of Abuse Testing
- Mesa Biotech Launches Molecular Test System at AACC 2019
- Ortho Clinical Diagnostics Highlights Groundbreaking Lab Technology
- Abbott Diagnostics Exhibits POC Diagnostics Solutions at AACC
- Beckman Coulter Demonstrates Latest Innovations in Lab Medicine
- Orion Diagnostica Showcases Range of Products in Anaheim
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








